Prognostic significance of CD155 mRNA expression in soft tissue sarcomas

Atsumi,Satoru; Matsumine,Akihiko; Toyoda,Hidemi; Niimi,Rui; Iino,Takahiro; Sudo,Akihiro

doi:10.3892/ol.2013.1280

Prognostic significance of CD155 mRNA expression in soft tissue sarcomas

Authors:
- Satoru Atsumi
- Akihiko Matsumine
- Hidemi Toyoda
- Rui Niimi
- Takahiro Iino
- Akihiro Sudo
View Affiliations

Affiliations: Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie 514‑8507, Japan, Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Mie 514‑8507, Japan
Published online on: April 2, 2013 https://doi.org/10.3892/ol.2013.1280
Pages: 1771-1776

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CD155 was initially identified as a receptor for poliovirus. Several studies have demonstrated that CD155 overexpression in cancer cells is significant in their migration, invasion, proliferation and metastasis. The objective of the present study was to investigate the correlation between CD155 expression and the clinical aggressiveness of soft tissue tumors. The CD155 expression levels in 43 surgically‑resected soft tissue tumors were evaluated using the quantitative real‑time polymerase chain reaction (PCR). The clinicopathogical factors affecting the expression levels of CD155 mRNA were investigated and the association between the expression levels of CD155 and patient prognosis was identified. The CD155 expression level was not correlated with the patient gender, site of the primary tumor, tumor depth, tumor size or presence of distant metastasis at presentation, but was correlated with patient age (Fisher's exact test). The local recurrence‑free survival rate for patients with a high CD155 expression level was observed to be significantly poorer compared with that of patients with low CD155 expression levels (P=0.0401). Moreover, a multivariate analysis indicated that a high CD155 expression level was an independent adverse prognostic factor for local recurrence‑free survival (hazard ratio, 6.369; P=0.0328). The present study therefore suggests that the expression level of CD155 is a useful marker for predicting the local recurrence of soft tissue tumors.

View Figures

View References

1	Weiss SW and Goldblum JR: General considerations. Enzinger and Weiss’s Soft Tissue Tumors. Weiss SW and Goldblum JR: 4th edition. Mosby Inc; St Louis, MO: pp. 1–19. 2001
2	Coindre JM, Terrier P, Guillou L, et al: Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 91:1914–1926. 2001. View Article : Google Scholar
3	Frustaci S, Gherlinzoni F, De Paoli A, et al: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 19:1238–1247. 2001.PubMed/NCBI
4	Guillou L, Coindre JM, Bonichon F, et al: Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 15:350–362. 1997.
5	Oliveira AM and Nascimento AG: Grading in soft tissue tumors: principles and problems. Skeletal Radiol. 30:543–559. 2001. View Article : Google Scholar : PubMed/NCBI
6	Troup S, Njue C, Kliewer EV, et al: Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res. 9:207–214. 2003.PubMed/NCBI
7	Matsumine A, Shintani K, Kusuzaki K, et al: Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors. J Surg Oncol. 96:411–418. 2007. View Article : Google Scholar : PubMed/NCBI
8	Shintani K, Matsumine A, Kusuzaki K, et al: Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch. 449:673–681. 2006. View Article : Google Scholar : PubMed/NCBI
9	Nakamura T, Matsumine A, Matsubara T, Asanuma K, Uchida A and Sudo A: Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. Cancer. 118:1055–1061. 2012. View Article : Google Scholar
10	Nobis P, Zibirre R, Meyer G, Kühne J, Warnecke G and Koch G: Production of a monoclonal antibody against an epitope on HeLa cells that is the functional poliovirus binding site. J Gen Virol. 66:2563–2569. 1985. View Article : Google Scholar : PubMed/NCBI
11	Mendelsohn CL, Wimmer E and Racaniello VR: Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin super-family. Cell. 56:855–865. 1989. View Article : Google Scholar : PubMed/NCBI
12	Takai Y, Irie K, Shimizu K, Sakisaka T and Ikeda W: Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization. Cancer Sci. 94:655–667. 2003. View Article : Google Scholar : PubMed/NCBI
13	Takai Y, Miyoshi J, Ikeda W and Ogita H: Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol. 9:603–615. 2008. View Article : Google Scholar : PubMed/NCBI
14	Amano H, Ikeda W, Kawano S, et al: Interaction and localization of Necl-5 and PDGF receptor beta at the leading edges of moving NIH3T3 cells: Implications for directional cell movement. Genes Cells. 13:269–284. 2008. View Article : Google Scholar : PubMed/NCBI
15	Irie K, Shimizu K, Sakisaka T, Ikeda W and Takai Y: Roles and modes of action of nectins in cell-cell adhesion. Semin Cell Dev Biol. 15:643–656. 2004. View Article : Google Scholar : PubMed/NCBI
16	Ogita H and Takai Y: Nectins and nectin-like molecules: roles in cell adhesion, polarization, movement, and proliferation. IUBMB Life. 58:334–343. 2006. View Article : Google Scholar : PubMed/NCBI
17	Masson D, Jarry A, Baury B, et al: Overexpression of CD155 gene in human colorectal carcinoma. Gut. 49:236–240. 2001. View Article : Google Scholar : PubMed/NCBI
18	Solecki D, Wimmer E, Lipp M and Bernhardt G: Identification and characterization of the cis-acting elements of the human CD155 gene core promoter. J Biol Chem. 274:1791–1800. 1999. View Article : Google Scholar : PubMed/NCBI
19	Solecki D, Bernhardt G, Lipp M and Wimmer E: Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene. J Biol Chem. 275:12453–12462. 2000. View Article : Google Scholar : PubMed/NCBI
20	Sloan KE, Eustace BK, Stewart JK, et al: CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer. 4:732004. View Article : Google Scholar : PubMed/NCBI
21	Ikeda W, Kakunaga S, Takekuni K, et al: Nectin-like molecule-5/Tage4 enhances cell migration in an integrin-dependent, nectin-3-independent manner. J Biol Chem. 279:18015–18025. 2004. View Article : Google Scholar : PubMed/NCBI
22	Kakunaga S, Ikeda W, Shingai T, et al: Enhancement of serum- and platelet-derived growth factor-induced cell proliferation by Necl-5/Tage4/poliovirus receptor/CD155 through the Ras-Raf-MEK-ERK signaling. J Biol Chem. 279:36419–36425. 2004. View Article : Google Scholar : PubMed/NCBI
23	Ikeda W, Kakunaga S, Itoh S, et al: Tage4/Nectin-like molecule-5 heterophilically trans-interacts with cell adhesion molecule Nectin-3 and enhances cell migration. J Biol Chem. 278:28167–28172. 2003. View Article : Google Scholar : PubMed/NCBI
24	Abe A, Fukui H, Fujii S, et al: Role of Necl-5 in the pathophysiology of colorectal lesions induced by dimethylhydrazine and/or dextran sodium sulphate. J Pathol. 217:42–53. 2009. View Article : Google Scholar : PubMed/NCBI
25	Nakai R, Maniwa Y, Tanaka Y, et al: Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. Cancer Sci. 101:1326–1330. 2010. View Article : Google Scholar : PubMed/NCBI
26	Atsumi S, Matsumine A, Toyoda H, et al: Oncolytic virotherapy for human bone and soft tissue sarcomas using live-attenuated poliovirus. Int J Oncol. 41:893–902. 2012.PubMed/NCBI
27	Enloe BM and Jay DG: Inhibition of Necl-5 (CD155/PVR) reduces glioblastoma dispersal and decreases MMP-2 expression and activity. J Neurooncol. 102:225–235. 2011. View Article : Google Scholar : PubMed/NCBI
28	Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD and Gromeier M: Polovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol. 6:208–217. 2004. View Article : Google Scholar : PubMed/NCBI
29	Toyoda H, Ido M, Hayashi T, Gabbazza EC, et al: Experimental treatment of human neuroblastoma using live-attenuated poliovirus. Int J Oncol. 24:49–58. 2004.PubMed/NCBI
30	Minami Y, Ikeda W, Kajita M, et al: Necl-5/poliovirus receptor interacts in cis with integrin alphaVbeta3 and regulates its clustering and focal complex formation. J Biol Chem. 282:18481–18496. 2007. View Article : Google Scholar : PubMed/NCBI
31	Tonn JC, Kerkau S, Hanke A, et al: Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer. 80:764–772. 1999. View Article : Google Scholar : PubMed/NCBI
32	Ren RB, Costantini F, Gorgacz EJ, Lee JJ and Racaniello VR: Transgenic mice expressing a human poliovirus receptor: a newmodel for poliomyelitis. Cell. 63:353–362. 1990. View Article : Google Scholar : PubMed/NCBI
33	Koike S, Taya C, Kurata T, et al: Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci USA. 88:951–955. 1991. View Article : Google Scholar